The estimated Net Worth of Jeffrey Kunin is at least $159 Thousand dollars as of 14 September 2022. Dr Kunin owns over 291,368 units of Novabay Pharmaceuticals Inc stock worth over $99,997 and over the last 3 years he sold NBY stock worth over $59,137.
Sign up
Dr D NBY stock SEC Form 4 insiders trading
Dr has made over 8 trades of the Novabay Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1 units of NBY stock worth $2 on 6 December 2022.
The largest trade he's ever made was selling 291,368 units of Novabay Pharmaceuticals Inc stock on 14 September 2022 worth over $46,619. On average, Dr trades about 99,666 units every 47 days since 2021. As of 14 September 2022 he still owns at least 208,632 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Dr Kunin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Jeffrey Kunin M.D. biography
Dr. Jeffrey Kunin M.D. is the Pres of DERMAdoctor at Novabay Pharmaceuticals Inc.
How old is Dr D?
Dr D is 58, he's been the Pres of DERMAdoctor of Novabay Pharmaceuticals Inc since . There are 3 older and 6 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.
What's Dr D's mailing address?
Jeffrey's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.
Insiders trading at Novabay Pharmaceuticals Inc
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd..., and Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
What does Novabay Pharmaceuticals Inc's logo look like?
Complete history of Dr Kunin stock trades at Novabay Pharmaceuticals Inc
Novabay Pharmaceuticals Inc executives and stock owners
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Justin M. Hall Esq.,
Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director -
Justin Hall,
President, Chief Executive Officer, Director -
Andrew Jones,
Chief Financial Officer, Treasurer -
Swan Sit,
Independent Director -
Yenyou Zheng,
Independent Director -
Paul Freiman,
Independent Director -
Mijia Wu,
Director -
Xinzhou Li,
Director -
Dr. Jeffrey Kunin M.D.,
Pres of DERMAdoctor -
Dr. Audrey Kunin M.D.,
Chief Product Officer -
Yongxiang Zheng,
Director -
Julie Garlikov,
Director -
Wang Xu,
NEO - Sr Mgr and Controller -
Lewis J Stuart,
Chief Commercial Officer -
Yanbin Liu,
Director -
Jason Philip Raleigh,
Interim CFO and Treasurer -
Xiaoyan Liu,
Director -
Gail J Maderis,
Director -
Todd Erik Zavodnick,
Director -
Pharma (Singapore) Pte. Ltd...,
10% owner -
T. Alex Mc Pherson,
Director -
Thomas J Paulson,
Chief Financial Officer -
Yonghao Ma,
Director -
Jian Ping Fu,
10% owner -
Massimo Radaelli,
Director -
Mark M Sieczkarek,
Director -
Pharma (Hong Kong) Co Ltd P...,
10% owner -
John Joseph Mc Govern,
Int Pres, CEO, CFO & Treasurer -
John James O'reilly,
Chief Financial Officer -
Colin Scott,
VP, Clinical Research & Dev't -
Keith R Bley,
SVP Product Development -
Pioneer Pharma Holdings Ltd...,
10% owner -
Roy J Wu,
SVP Bus & Corp Development -
David W. Stroman,
SVP, Ophthalmic Product Devt. -
Tony D.S. Wicks,
Director -
Anthony Dailley,
Director -
Robert R. Tufts,
Director -
Charles Cashion,
Director -
Behzad Khosrovi,
VP, Research & Dev't -
Ramin Najafi,
Chief Executive Officer -
Area Pioneer Pharma Co., Lt...,
10% owner -
Ramin Najafi Family Trust D...,
Chief Executive Officer -
Mark Brian Anderson,
CSO -
Harry F Jr Hixson,
Director -
Russell A. Hoon,
Senior Vice President -
Xiaopei Wang,
-
Jeffrey Kunin,
President, DERMAdoctor, LLC -
Audrey Kunin,
Chief Product Officer